



Core One Labs, Inc.

Suite 3123 – 595 Burrard Street
Vancouver, BC V7X 1J1
P:+1(866) 347-5058
E: info@core1labs.com
www.core1labs.com



Company Overview — October 2021

Core One Labs, Inc. (OTC PINK: CLABF) (CSE: COOL) - Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”), which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics, which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Company Statistics

Ticker: (OTC PINK) – **CLABF**

Price (10/13/2021): \$1.69

52 Week Range: \$0.94 - \$10.40

Shares Outstanding: 15,506,925

Market Cap: \$25,276,288

Source: *OTCMarkets.com, Yahoo Finance & SEC.gov*

Recent News

August 15th, 2021 - Core One Labs Applauds TheraPsil on Its Submission to Health Canada

August 13th, 2021 - Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

August 7th, 2021 - Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

August 5th, 2021 - Core One Labs’ Virtual Town Hall Reveals Company is Nearing Production of Biosynthesized Psilocybin: Breakthrough In the Psychedelic Space Expected Upon Successful Completion

July 30th, 2021 - Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021

Core One Labs Investment Catalysts

➤ R&D

- Proprietary technology
- API Grade Biosynthesized Psilocybin
- Operating Under Health Canada Licensed Dealer Labs

➤ Valuation

- Well funded
- Trading at a discount relative to peers

➤ Delivery System

- Patent Pending Thinstrip technology
- Chemically synthesized compounds and new drug formulations.

➤ Clinics

- 250,000 + potential patients
- Development of Clinical Research and Trials
- Goal to Expand to new locations

Biosynthetic Psilocybin Advantages

Scientific

- Optimized, fully synthetic constructs.
- Producer strain is optimized.
- All required enzymes are produced with no inhibitory sequences (no excess).

Financial

- Estimated Market price is \$7,000 to \$10,000 USD per gram for synthetic psilocybin used in clinical trials. By using **our biosynthetic expression system**, pharma-grade psilocybin can be produced cost effectively for **\$10s to \$100s** of dollars.
- By using a biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively and accurately, and purified, for a fraction of the cost of other methods.



Key Management

Dr. Robert Hancock,

Executive Chairman,

Dr. Hancock is a leading microbiologist in Canada and has researched and taught at the University of British Columbia for nearly 40 years. Dr. Hancock OC, OBC, FRSC, is a Canada Research Chair holder in Health and Genomics, a Director of the Centre for Microbial Diseases and Immunity Research and a holder of the Order of Canada for his contributions in these and other fields.

Joel Shacker,

Chief Executive Officer

Mr. Shacker has worked extensively in the cannabis and finance space, having been CEO of a vertically integrated, fully licensed, non-psychoactive cannabidiol (CBD) business with international subsidiaries. Mr. Shacker has expansive experience in M&A across North America, South America, and Europe.

Geoff Balderson,

Chief Financial Officer

Mr. Balderson has over 17 years of capital market experience. Mr. Balderson is an officer and director of various TSX Venture listed companies. Mr. Balderson is a former Investment Advisor with two Canadian Securities dealers, and a graduate of the University of British Columbia.

Investor Relations Contact

James S. Painter III, CEO
Emerging Markets Consulting, LLC
Jamespainter@emergingmarketsllc.com
321-206-6682

17(B) Compensation Disclosure:

Compensation Disclosure: Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described.

EMC has been paid \$240,000 from Core One Labs, Inc. for various marketing services including this Factsheet.

<https://emergingmarketsconsulting.com/disclaimer/>

THINSTRIPS Technology

- Core One Lab's infused thinstrips will allow for efficient bioavailability (absorption) as well as controlled dosing of active ingredients and can be used to administer multiple API's.
- Using their patent pending Thinstrip technology, Core One Lab's endeavor to advance psychedelics as alternative medicine and to deliver APIs to clients in our medical clinics, as well as license Core One Lab's Thinstrip technology to other drug providers.



Core One Labs Medical Offices

5 CLINICS

4 in British Columbia, Canada

1 in Texas, United States

Patient Database
+250k

Expansion Plan

Leveraging existing SOPs, data driven research sets, and practitioner education modules, will roll out clinics across Canada and the United States.



R&D Recent Milestones

- Operating Under Health Canada–certified Controlled Substances Licensed Lab For Production Of Psilocybin (Located In Victoria, Bc, Canada)*
- Lab Equipment For Research & Development Has Been Purchased*
- Proprietary DNA Sequences In Final Stages Of Development*
- Optimized Producer Strain Constructed
- Patent Submission Is Underway By Gowling LLP

*Operating under Green Sky Lab's license for possession, production, sale/provision and sending, transportation and delivery of product.

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual future results may be materially different from what we expect due to risks related to our ability to raise additional funds, the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, future competition, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the SEC. These forward-looking statements speak only as of the date of this communication and the Company undertakes no obligation to revise or update any forward-looking statements for any reason.